SciELO - Scientific Electronic Library Online

 
vol.54 número1Attention deficit disorder: treatment with methylphenidateRural or urban living and Parkinson's disease índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Arquivos de Neuro-Psiquiatria

versión impresa ISSN 0004-282X

Resumen

MATTOS, James Pitágoras de; ROSSO, Ana Lúcia Zuma de  y  NOVIS, Sérgio. Dystonias: clinical and therapeutic features in 64 patients. Arq. Neuro-Psiquiatr. [online]. 1996, vol.54, n.1, pp. 30-36. ISSN 0004-282X.  http://dx.doi.org/10.1590/S0004-282X1996000100005.

The experience with 64 patients with dystonia seen at the Extrapyramidal Diseases Sector of the Neurology Department of the Hospital Universitário Clementino Fraga Filho of the UFRJ is presented as well as the pertinent review of the literature. The five-and-a-half-year of follow-up showed that 33 were male and 31 female; 48 were white, 10 mulatto and 6 negro; the mean time of disease was 9 years and 8 months. According to the distribution of the movement disorder, 30 (46.9%) were focal, 17 (26.6%) segmental, 13 (20.3%) generalized, 3 (4.7%) hemidystonia and 1 (1.5%) multifocal. In 11 (17.2%) the age of onset was before 12 years old, in 6 (9.4%) between 13 and 20 years old, and in 47 (73.4%) after 20 years old. According to the etiology, 39 (60.9%) were idiopathic sporadic, 6 (9.4%) were idiopathic familial and 19 (29.7%) were symptomatic. The therapeutical approach used in these patients were anticholinergic drugs, dopaminergic agonists or antagonists and baclofen, alone or associated with anticholinergic drugs for generalized dystonia. The authors conclude that botulinum toxin type A is the most valuable therapeutic agent in the treatment of focal dystonia.

Palabras llave : dystonia; dystonia musculorum deformans; botulinum toxin.

        · resumen en Portugués     · texto en Portugués     · pdf en Portugués